$ARTH
Arch Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000143774923023364 Filed on August 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $39.52K $13.29K
YoY Change 2417.2% 112.31%
Cost Of Revenue $23.28K $18.53K
YoY Change 17807.69% 8.1%
Gross Profit $16.24K -$5.236K
YoY Change 1027.78% -51.87%
Gross Profit Margin 41.09% -39.39%
Selling, General & Admin $1.145M $870.1K
YoY Change -5.45% 4.05%
% of Gross Profit 7053.02%
Research & Development $199.8K $139.0K
YoY Change -13.61% -13.01%
% of Gross Profit 1229.99%
Depreciation & Amortization $1.970K $273.00
YoY Change 146.25% -65.83%
% of Gross Profit 12.13%
Operating Expenses $1.345M $1.009M
YoY Change -6.76% 1.31%
Operating Profit -$1.329M -$1.014M
YoY Change -7.79% 0.73%
Interest Expense -$1.128M $808.8K
YoY Change 152.2% 1927.5%
% of Operating Profit
Other Income/Expense, Net -$808.8K
YoY Change 1927.5%
Pretax Income -$2.457M -$1.823M
YoY Change 30.11% 74.16%
Income Tax
% Of Pretax Income
Net Earnings -$2.457M -$1.823M
YoY Change 30.11% 74.16%
Net Earnings / Revenue -6217.61% -13714.79%
Basic Earnings Per Share -$1.42
Diluted Earnings Per Share -$1.36 -$1.42
COMMON SHARES
Basic Shares Outstanding 3.094M 1.285M
Diluted Shares Outstanding 1.280M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $222.7K $86.54K
YoY Change -70.18% 57.35%
Cash & Equivalents $222.7K $86.54K
Short-Term Investments
Other Short-Term Assets $362.9K $90.54K
YoY Change -16.85% 8.44%
Inventory $1.365M $1.383M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.950M $1.560M
YoY Change -24.94% -0.43%
LONG-TERM ASSETS
Property, Plant & Equipment $4.599K $728.00
YoY Change 125.0% -74.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.500K $3.500K
YoY Change 0.0% 0.0%
Total Long-Term Assets $8.099K $4.228K
YoY Change 46.09% -33.34%
TOTAL ASSETS
Total Short-Term Assets $1.950M $1.560M
Total Long-Term Assets $8.099K $4.228K
Total Assets $1.958M $1.564M
YoY Change -24.79% -0.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.304M $2.471M
YoY Change 73.51% 45.69%
Accrued Expenses $1.291M $1.021M
YoY Change 189.19% 357.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $5.628M $5.347M
YoY Change 923.24%
Total Short-Term Liabilities $9.466M $9.579M
YoY Change 185.08% 399.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.466M $9.579M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $9.466M $9.579M
YoY Change 39.28% 71.41%
SHAREHOLDERS EQUITY
Retained Earnings -$62.06M -$59.60M
YoY Change 12.68% 12.06%
Common Stock $54.55M $51.58M
YoY Change 7.21% 21665.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$7.508M -$8.015M
YoY Change
Total Liabilities & Shareholders Equity $1.958M $1.564M
YoY Change -24.79% -0.56%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$2.457M -$1.823M
YoY Change 30.11% 74.16%
Depreciation, Depletion And Amortization $1.970K $273.00
YoY Change 146.25% -65.83%
Cash From Operating Activities -$1.224M -$897.5K
YoY Change -26.67% 56.26%
INVESTING ACTIVITIES
Capital Expenditures $4.520K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$4.520K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.365M 954.6K
YoY Change -42.22% 66.02%
NET CHANGE
Cash From Operating Activities -1.224M -897.5K
Cash From Investing Activities -4.520K
Cash From Financing Activities 1.365M 954.6K
Net Change In Cash 135.8K 57.04K
YoY Change -80.38% 9567.8%
FREE CASH FLOW
Cash From Operating Activities -$1.224M -$897.5K
Capital Expenditures $4.520K
Free Cash Flow -$1.229M
YoY Change -26.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
12000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1285213
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1285213
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
1285 usd
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
51582100 usd
CY2023Q2 arch Shareholder Advances Current
ShareholderAdvancesCurrent
50000 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1252734
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1249432
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1252 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
50878718 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59598413 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55072773 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-8015028 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4192803 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1564246 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2603739 usd
CY2023Q2 us-gaap Revenues
Revenues
13293 usd
CY2022Q2 us-gaap Revenues
Revenues
6261 usd
us-gaap Revenues
Revenues
36207 usd
us-gaap Revenues
Revenues
14086 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
18529 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
17140 usd
us-gaap Cost Of Revenue
CostOfRevenue
54882 usd
us-gaap Cost Of Revenue
CostOfRevenue
51363 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
870053 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
836215 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
922120 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
1027630 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
1013201 usd
us-gaap Costs And Expenses
CostsAndExpenses
3751770 usd
us-gaap Costs And Expenses
CostsAndExpenses
4281710 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1014337 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1006940 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3715563 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4267624 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
808770 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
39890 usd
us-gaap Interest Expense
InterestExpense
1968274 usd
CY2022Q2 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
0 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
1158197 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
0 usd
CY2023Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 usd
CY2022Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1000000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-808770 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-39890 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.42
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.86
CY2023Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1279967
CY2022Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1184738
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1265340
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1184266
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-6386088 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1823107 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001537561
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2022Q4 arch Shareholder Advances Current
ShareholderAdvancesCurrent
0 usd
CY2023Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
690015 usd
CY2022Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
820509 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
127781 usd
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
748275 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9579274 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3320494 usd
CY2023Q2 arch Interest Payable Noncurrent
InterestPayableNoncurrent
0 usd
CY2022Q4 arch Interest Payable Noncurrent
InterestPayableNoncurrent
204575 usd
CY2023Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
459200 usd
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3476048 usd
CY2023Q2 us-gaap Liabilities
Liabilities
9579274 usd
CY2022Q4 us-gaap Liabilities
Liabilities
6796542 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3225753 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3308227 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
139048 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
159846 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
471135 usd
us-gaap Interest Expense
InterestExpense
119671 usd
CY2023Q2 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
0 usd
us-gaap Net Income Loss
NetIncomeLoss
-4525640 usd
us-gaap Net Income Loss
NetIncomeLoss
-3387295 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
41259 usd
CY2023Q2 arch Stock And Warrants Issued During Period Value New Issues Net Of Financing Costs
StockAndWarrantsIssuedDuringPeriodValueNewIssuesNetOfFinancingCosts
152908 usd
CY2023Q2 arch Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
0 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-8015028 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-4192803 usd
us-gaap Net Income Loss
NetIncomeLoss
-4525640 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
213809 usd
arch Stock And Warrants Issued During Period Value New Issues Net Of Financing Costs
StockAndWarrantsIssuedDuringPeriodValueNewIssuesNetOfFinancingCosts
440328 usd
arch Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
arch Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
49278 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-8015028 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-3059424 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1046830 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
90755 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-4015499 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-1025674 usd
us-gaap Net Income Loss
NetIncomeLoss
-3387295 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
397470 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-4015499 usd
us-gaap Net Income Loss
NetIncomeLoss
-4525640 usd
us-gaap Net Income Loss
NetIncomeLoss
-3387295 usd
us-gaap Depreciation
Depreciation
1316 usd
us-gaap Depreciation
Depreciation
2397 usd
us-gaap Share Based Compensation
ShareBasedCompensation
213809 usd
us-gaap Share Based Compensation
ShareBasedCompensation
397470 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-0 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1000000 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
1158197 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-0 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
1480121 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
0 usd
us-gaap Inventory Write Down
InventoryWriteDown
0 usd
us-gaap Inventory Write Down
InventoryWriteDown
248073 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-31910 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-345869 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
247933 usd
arch Proceeds From Shareholder Advances
ProceedsFromShareholderAdvances
1228015 usd
arch Proceeds From Shareholder Advances
ProceedsFromShareholderAdvances
575000 usd
arch Proceeds From Issuance Of Common Stock And Warrants Net Of Financing Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfFinancingCosts
507000 usd
arch Proceeds From Issuance Of Common Stock And Warrants Net Of Financing Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfFinancingCosts
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1487082 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-660398 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
746940 usd
arch Warrants Exchanged For Common Stock Noncash
WarrantsExchangedForCommonStockNoncash
49278 usd
arch Warrants Exchanged For Common Stock Noncash
WarrantsExchangedForCommonStockNoncash
0 usd
arch Issuance Of Restricted Stock
IssuanceOfRestrictedStock
3019 usd
arch Issuance Of Restricted Stock
IssuanceOfRestrictedStock
29831 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
1158197 usd
CY2023Q2 arch Reclassification Of Exchanged Notes Included In Notes Payable To Unsecured Convertible Notes
ReclassificationOfExchangedNotesIncludedInNotesPayableToUnsecuredConvertibleNotes
699781 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33756 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33756 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
33028 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31712 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
728 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2044 usd
CY2023Q2 us-gaap Depreciation
Depreciation
273 usd
CY2022Q2 us-gaap Depreciation
Depreciation
799 usd
us-gaap Depreciation
Depreciation
1316 usd
us-gaap Depreciation
Depreciation
2397 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
56828 usd
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
9063 usd
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1326110 usd
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1405785 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
1382938 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
1414848 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
98626
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.00
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y4M9D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16900 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
24500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
19101
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
70.00
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
104025
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
39.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y8M19D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
79409
arch Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
48.00
arch Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P4Y10M6D
arch Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue
0 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
104325
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
39.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y8M19D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
20.00
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
-0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
20.00
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
20.00
CY2016Q3 arch Shelf Registration Statement Maximum Amount Authorized
ShelfRegistrationStatementMaximumAmountAuthorized
50000000 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
1158197 usd
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
215625
CY2022Q3 arch Percentage Of Principal Amount
PercentageOfPrincipalAmount
0.15 pure
CY2022Q3 arch Proceeds From Issuance Of Convertible Notes Common Stock And Warrants Gross
ProceedsFromIssuanceOfConvertibleNotesCommonStockAndWarrantsGross
3500000 usd
CY2022Q3 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
775000 usd
CY2022Q3 arch Placement Agents Fees
PlacementAgentsFees
555000 usd
CY2023Q1 arch Proceeds From Issuance Of Convertible Notes Common Stock And Warrants Gross
ProceedsFromIssuanceOfConvertibleNotesCommonStockAndWarrantsGross
530000 usd
arch Placement Agents Fees
PlacementAgentsFees
15000 usd
CY2023Q2 arch Proceeds From Issuance Of Convertible Notes Common Stock And Warrants Gross
ProceedsFromIssuanceOfConvertibleNotesCommonStockAndWarrantsGross
488000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25840 usd
arch Proceeds From Shareholder Advances
ProceedsFromShareholderAdvances
538000 usd
CY2023Q2 arch Advance Expected To Roll Into Nearterm Capital Raise
AdvanceExpectedToRollIntoNeartermCapitalRaise
340000 usd
CY2023Q2 arch Advance Expected To Roll Into Nearterm Capital Raise
AdvanceExpectedToRollIntoNeartermCapitalRaise
350015 usd
arch Proceeds From Shareholder Advances
ProceedsFromShareholderAdvances
538000 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
12000000

Files In Submission

Name View Source Status
0001437749-23-023364-index-headers.html Edgar Link pending
0001437749-23-023364-index.html Edgar Link pending
0001437749-23-023364.txt Edgar Link pending
0001437749-23-023364-xbrl.zip Edgar Link pending
arch-20230630.xsd Edgar Link pending
arch20230630_10q.htm Edgar Link pending
ex_543144.htm Edgar Link pending
ex_543145.htm Edgar Link pending
arch-20230630_cal.xml Edgar Link unprocessable
arch-20230630_def.xml Edgar Link unprocessable
arch-20230630_lab.xml Edgar Link unprocessable
arch-20230630_pre.xml Edgar Link unprocessable
arch20230630_10q_htm.xml Edgar Link completed
ex_543146.htm Edgar Link pending
ex_554640.htm Edgar Link pending
ex_554641.htm Edgar Link pending
ex_554642.htm Edgar Link pending
ex_554643.htm Edgar Link pending
ex_554644.htm Edgar Link pending
ex_557783.htm Edgar Link pending
ex_557784.htm Edgar Link pending
ex_557785.htm Edgar Link pending
ex_557786.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable